Geron Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp.

GERN 1.160

+7.9%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: cycleupcycledown who wrote (3281)	6/5/2011 1:15:13 PM
From: cycleupcycledown	of 3576

I'm pretty good at predicting stuff......just a wild guess though....I predict GERN rallies soon off partner news.........".Geron Corp., the company conducting the first U.S.-authorized trial of human embryonic stem cells, said Chief Executive Officer Thomas B. Okarma has stepped aside as the company focuses on making deals with drugmakers. Okarma will remain with Geron as a consultant while Chief Financial officer David L. Greenwood takes over as interim CEO, president and a member of the board of directors, the Menlo Park, California-based company said in a statement. Geron began in October the first of three stages of testing usually required by regulators for its embryonic stem-cell therapy in spinal-cord injury patients. The company also has three clinical trials under way testing therapies to treat cancer. The change in leadership shows the company wants to focus on creating partnerships that can advance its products, said Ren Benjamin, an analyst with Rodman & Renshaw

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next